JANX is expected to report earnings to fall -36% to -34 cents per share on May 07

A.I.dvisor
at Tickeron.com
05/06/24
Loading...
JANX - Janux Therapeutics
Janux Therapeutics Earnings Graph
Q1'24
Est.
$-0.34
Q4'23
Beat
by $0.17
Q3'23
Beat
by $0.22
Q2'23
Beat
by $0.08
Q1'23
Beat
by $0.07
The last earnings report on December 31 showed earnings per share of -25 cents, beating the estimate of -42 cents. P/B Ratio (9.756) is normal, around the industry mean (10.296). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). JANX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). JANX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (357.143) is also within normal values, averaging (233.055). With 1.05M shares outstanding, the current market capitalization sits at 3.36B.
View a ticker or compare two or three
JANXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com